23-Valent Pneumococcal Polysaccharide Vaccine Market

Executive Summary

23-Valent Pneumococcal Polysaccharide Vaccine Market was valued at US $9.06 billion in 2021 and is projected to grow at 7.82% CAGR over the forecast period to reach US $14.23 billion by 2027. 23-Valent Pneumococcal Polysaccharide Vaccine Market represented US $1.27 billion opportunity over 2019-2021 and estimated to create US $5.17 billion opportunity in 2027 over 2021.

23-Valent Pneumococcal Polysaccharide Vaccine from Consainsights analyses the 23-Valent Pneumococcal Polysaccharide Vaccine Market in the Life Sciences industry over the forecast period to 2027.

23-Valent Pneumococcal Polysaccharide Vaccine research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

23-Valent Pneumococcal Polysaccharide Vaccine segmentation includes Dose Type, Age-group and Geography.

Based on the Dose Type, the 23-Valent Pneumococcal Polysaccharide Vaccine analysis covers SINGLE DOSE VIAL, PRE-FILLED SYRINGE.

In Dose Type segment, SINGLE DOSE VIAL segment has highest cagr growth of 6.92%.

Based on the Age-group, the 23-Valent Pneumococcal Polysaccharide Vaccine analysis covers CHILDREN (2-10 YEARS), ADULTS (10-64 YEARS), GERIATRICS (65 YEARS AND ABOVE).

In Age-group segment, CHILDREN (2-10 YEARS) segment has highest cagr growth of 6.92%.

Based on the region, the 23-Valent Pneumococcal Polysaccharide Vaccine analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include PFIZER INC., SANOFI S.A., GLAXOSMITHKLINE PLC, MERCK & CO., ASTRAZENECA, BAXTER INTERNATIONAL INC., BEIJING MINHAI BIOTECHNOLOGY, SERUM INSTITUTE OF INDIA, BIOGEN INC., ELI LILLY AND COMPANY and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Dose Type

Introduction

In 2021, SINGLE DOSE VIAL segment has the highest revenue of US $4.25 billion and is expected to grow at CAGR of 6.92% by 2027 SINGLE DOSE VIAL segment has highest cagr growth of 6.92%.

SINGLE DOSE VIAL

SINGLE DOSE VIAL segment was valued at US $3.66 billion in 2019 and is projected to grow at 6.92% CAGR over the forecast period to reach US $6.68 billion by 2027. SINGLE DOSE VIAL segment represented US $0.59 billion opportunity over 2019-2021 and estimated to create US $2.43 billion opportunity in 2027 over 2021.

PRE-FILLED SYRINGE

PRE-FILLED SYRINGE segment was valued at US $2.25 billion in 2019 and is projected to grow at 6.92% CAGR over the forecast period to reach US $4.11 billion by 2027. PRE-FILLED SYRINGE segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.49 billion opportunity in 2027 over 2021.

Age-group

Introduction

In 2021, CHILDREN (2-10 YEARS) segment has the highest revenue of US $4.32 billion and is expected to grow at CAGR of 6.92% by 2027 CHILDREN (2-10 YEARS) segment has highest cagr growth of 6.92%.

CHILDREN (2-10 YEARS)

CHILDREN (2-10 YEARS) segment was valued at US $3.71 billion in 2019 and is projected to grow at 6.92% CAGR over the forecast period to reach US $6.78 billion by 2027. CHILDREN (2-10 YEARS) segment represented US $0.60 billion opportunity over 2019-2021 and estimated to create US $2.47 billion opportunity in 2027 over 2021.

ADULTS (10-64 YEARS)

ADULTS (10-64 YEARS) segment was valued at US $3.54 billion in 2019 and is projected to grow at 6.92% CAGR over the forecast period to reach US $6.46 billion by 2027. ADULTS (10-64 YEARS) segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.35 billion opportunity in 2027 over 2021.

GERIATRICS (65 YEARS AND ABOVE)

GERIATRICS (65 YEARS AND ABOVE) segment was valued at US $0.54 billion in 2019 and is projected to grow at 6.92% CAGR over the forecast period to reach US $0.98 billion by 2027. GERIATRICS (65 YEARS AND ABOVE) segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.36 billion opportunity in 2027 over 2021.